Low prediagnostic levels of circulating adiponectin were associated with an increased risk of pancreatic cancer, according to a study published December 14 in the Journal of the National Cancer Institute.
Pancreatic cancer is the fourth leading cause of cancer death in the U.S., but its etiology remains unclear. Adiponectin, a hormone secreted from fat cells, has insulin-sensitizing and anti-inflammatory properties. Low adiponectin plasma levels are associated with the insulin resistance that manifests in obesity and diabetes mellitus, both of which are risk factors for pancreatic cancer.
In order to determine if prediagnostic plasma levels of adiponectin were linked to an increased risk of pancreatic cancer, Ying Bao, M.D., Sc.D., Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, and colleagues, pooled the data from five prospective U.S. cohort studies, and matched 468 pancreatic cancer case subjects with 1,080 healthy control subjects by cohort, year of birth, smoking status, fasting status, and month of blood draw. They assessed the association between adiponectin and pancreatic cancer risk with conditional logistic regression.
The researchers found a statistically significant inverse association between prediagnostic plasma adiponectin levels and the risk of pancreatic cancer in the five prospective cohorts. "Our data provide additional evidence for a biological link between obesity, insulin resistance, and pancreatic cancer risk and also suggest an independent role of adiponectin in the development of pancreatic cancer," the authors write.
In an accompanying editorial, Jianliang Zhang, Ph.D., Associate Professor of Oncology and Steven N. Hochwald, M.D., Department of Surgical Oncology, both of the Roswell Park Cancer Institute, write that the study establishes a link between adiponectin levels and pancreatic cancer risk that suggests that metabolism contributes to the pathophysiology of pancreatic cancer. "Early detection by the assessment of adiponectin has the potential to improve the survival rates of pancreatic tumor patients," the authors write. "It is also inviting to speculate that therapeutic interventions to increase the levels of circulating adiponectin may prevent the development of pancreatic cancer and/or improve the survival of patients with malignancy."
Journal of the National Cancer Institute: http://jncicancerspectrum.oupjournals.org
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Evidence was weak that marijuana helps anxiety and sleep disorders
Ageing doesn’t mean a steady descent into misery – evidence suggests that happiness is likely to increase as we head towards old age, but is it that simple?
The Ebola epidemic in Guinea that began early last year has set back the country's fight against malaria, say experts.
New diagnostics can find the DNA that drives a tumor, but evidence that they help patients is missing.
Scientists agree that children raised by same-sex couples are no worse off than children raised by parents of the opposite sex, according to a new study co-authored by a University of Oregon professor.
Children as young as 3 years old will step in to right the wrong if they see someone being mistreated, a study finds. But they aren't as keen as 5-year-olds to dole out punishment.
Millions suffer from SAD in summer as well as winter, and evidence hints that birth season plays a role in who develops the disorder
International panel says climate change is already affecting people's health, but there are steps we can take
A new federal study has answers
When Middle East respiratory syndrome erupted in South Korea, people started wearing masks everywhere, even at weddings. So how good are these masks at stopping MERS or even the flu?